pipamperone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tranquillizers, neuroleptics, 4'-fluoro-4-piperidinobutyrophenone derivatives 2181 1893-33-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pipamperone dihydrochloride
  • pipamperone
  • dipiperon
  • dipiperone
  • floropipamide
  • dipiperal
  • pipamperone hydrochloride
  • pipamperone HCl
  • Molecular weight: 375.49
  • Formula: C21H30FN3O2
  • CLOGP: 2.24
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 66.64
  • ALOGS: -3.31
  • ROTB: 7

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,MAP3K7,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,TEK 28
kinase-selectivity-class AKT3,AXL,BRAF,CAMK2D,CDK4,EIF2AK3,EPHB4,PDK4,PRKCD,SIK2,SIK3,STK33,TEK,TTK 14
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product prescribing error 127.12 39.69 49 4139 30096 90594163
General physical health deterioration 120.62 39.69 112 4076 355003 90269256
Suicide attempt 117.50 39.69 61 4127 75338 90548921
Vascular encephalopathy 106.72 39.69 20 4168 750 90623509
Tachycardia 103.03 39.69 73 4115 157600 90466659
Subileus 100.25 39.69 25 4163 3619 90620640
Hypotension 94.07 39.69 94 4094 325303 90298956
Fall 90.54 39.69 111 4077 481699 90142560
Hypothermia 90.26 39.69 32 4156 15543 90608716
Restlessness 89.34 39.69 40 4148 35680 90588579
Drug interaction 83.81 39.69 82 4106 276371 90347888
Labelled drug-drug interaction medication error 80.87 39.69 29 4159 14553 90609706
Dysarthria 78.91 39.69 42 4146 54440 90569819
Gastrointestinal sounds abnormal 75.98 39.69 21 4167 4522 90619737
Rhonchi 69.90 39.69 18 4170 2960 90621299
Somnolence 67.02 39.69 64 4124 209020 90415239
Facial nerve disorder 66.89 39.69 13 4175 592 90623667
Faecaloma 66.44 39.69 23 4165 10408 90613851
Electrocardiogram QT prolonged 60.25 39.69 39 4149 72417 90551842
Abdominal tenderness 57.23 39.69 20 4168 9304 90614955
Apathy 53.93 39.69 20 4168 11020 90613239
Syncope 53.03 39.69 46 4142 132617 90491642
Cerebrospinal fluid retention 52.25 39.69 8 4180 85 90624174
Electrocardiogram ST-T segment abnormal 51.99 39.69 10 4178 431 90623828
Ileus 49.39 39.69 21 4167 16525 90607734
Coma 48.20 39.69 34 4154 72598 90551661
Depressed level of consciousness 48.13 39.69 34 4154 72750 90551509
Thyroiditis 48.11 39.69 14 4174 3623 90620636
Brain contusion 47.89 39.69 10 4178 655 90623604
Tachypnoea 47.38 39.69 22 4166 21287 90602972
Pallor 45.70 39.69 25 4163 34140 90590119
Cerebral ventricular rupture 45.29 39.69 8 4180 214 90624045
Dementia 45.01 39.69 22 4166 23839 90600420
Bladder disorder 43.55 39.69 17 4171 10755 90613504
Arrhythmia 43.29 39.69 26 4162 42306 90581953
Parkinsonism 42.47 39.69 18 4170 14047 90610212
Rabbit syndrome 41.89 39.69 8 4180 332 90623927
Generalised tonic-clonic seizure 39.79 39.69 23 4165 34880 90589379

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Brain scan abnormal 161.28 34.37 34 3742 1205 42616354
Cerebral artery thrombosis 161.01 34.37 34 3742 1215 42616344
Areflexia 133.24 34.37 36 3740 3707 42613852
Hemiplegia 91.24 34.37 32 3744 7847 42609712
Paroxysmal perceptual alteration 90.71 34.37 16 3760 214 42617345
Oscillopsia 88.57 34.37 16 3760 247 42617312
Product monitoring error 79.37 34.37 25 3751 4398 42613161
Facial paralysis 76.72 34.37 32 3744 12531 42605028
Pleurothotonus 74.36 34.37 18 3758 1193 42616366
Ischaemic stroke 73.66 34.37 37 3739 22196 42595363
Neuroleptic malignant syndrome 71.91 34.37 36 3740 21436 42596123
Withdrawal syndrome 65.38 34.37 30 3746 14745 42602814
Wrong patient received product 63.23 34.37 20 3756 3563 42613996
Respiratory distress 61.45 34.37 41 3735 41779 42575780
General physical health deterioration 61.23 34.37 71 3705 151175 42466384
Bradyarrhythmia 60.22 34.37 18 3758 2657 42614902
Fall 54.66 34.37 84 3692 234436 42383123
Disease recurrence 53.24 34.37 33 3743 29645 42587914
Suicidal ideation 51.72 34.37 39 3737 48122 42569437
Photopsia 49.14 34.37 15 3761 2377 42615182
Hyperventilation 48.94 34.37 16 3760 3166 42614393
Congenital cystic kidney disease 45.13 34.37 10 3766 448 42617111
Disorientation 44.78 34.37 32 3744 36357 42581202
Drug withdrawal convulsions 43.55 34.37 12 3764 1326 42616233
Hangover 40.73 34.37 11 3765 1127 42616432
Delirium 40.40 34.37 35 3741 52484 42565075
Renal aplasia 39.79 34.37 10 3766 773 42616786
Depressed level of consciousness 39.00 34.37 33 3743 47937 42569622
Wound 38.42 34.37 22 3754 17095 42600464
Heart disease congenital 38.16 34.37 11 3765 1431 42616128
Product administration error 37.00 34.37 22 3754 18321 42599238
Restlessness 36.62 34.37 26 3750 29223 42588336
Conduction disorder 36.06 34.37 12 3764 2506 42615053

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 183.59 38.43 182 7323 425113 110156681
Brain scan abnormal 156.44 38.43 33 7472 1538 110580256
Cerebral artery thrombosis 148.80 38.43 32 7473 1636 110580158
Fall 148.71 38.43 193 7312 603289 109978505
Product prescribing error 137.82 38.43 68 7437 51263 110530531
Paroxysmal perceptual alteration 125.48 38.43 21 7484 269 110581525
Areflexia 117.20 38.43 35 7470 6734 110575060
Product monitoring error 115.84 38.43 37 7468 8890 110572904
Drug interaction 109.24 38.43 151 7354 500032 110081762
Restlessness 106.55 38.43 59 7446 56200 110525594
Labelled drug-drug interaction medication error 103.77 38.43 47 7458 29255 110552539
Hypotension 98.05 38.43 147 7358 523702 110058092
Vascular encephalopathy 97.67 38.43 20 7485 804 110580990
Pleurothotonus 95.08 38.43 24 7481 2474 110579320
Wrong patient received product 92.13 38.43 29 7476 6645 110575149
Oscillopsia 91.22 38.43 17 7488 415 110581379
Depressed level of consciousness 86.51 38.43 67 7438 112211 110469583
Subileus 84.83 38.43 27 7478 6410 110575384
Suicide attempt 84.71 38.43 64 7441 103330 110478464
Electrocardiogram QT prolonged 81.73 38.43 64 7441 108896 110472898
Apathy 80.35 38.43 33 7472 16206 110565588
Hypothermia 80.08 38.43 38 7467 26264 110555530
Dysarthria 80.04 38.43 57 7448 84064 110497730
Suicidal ideation 78.85 38.43 59 7446 93878 110487916
Somnolence 74.27 38.43 96 7409 297353 110284441
Neuroleptic malignant syndrome 73.60 38.43 39 7466 34020 110547774
Hemiplegia 63.55 38.43 31 7474 22751 110559043
Gastrointestinal sounds abnormal 62.18 38.43 21 7484 5997 110575797
Tachycardia 59.45 38.43 75 7430 226570 110355224
Facial paralysis 58.83 38.43 30 7475 24184 110557610
Ischaemic stroke 58.81 38.43 36 7469 41227 110540567
Facial nerve disorder 58.58 38.43 13 7492 769 110581025
Coma 57.26 38.43 54 7451 117815 110463979
Withdrawal syndrome 54.21 38.43 31 7474 31349 110550445
Bradyarrhythmia 54.08 38.43 18 7487 4916 110576878
Hyperventilation 54.05 38.43 21 7484 8926 110572868
Product administration error 51.84 38.43 32 7473 37185 110544609
Rhonchi 51.59 38.43 17 7488 4501 110577293
Respiratory distress 50.63 38.43 40 7465 68834 110512960
Abdominal tenderness 50.57 38.43 22 7483 12435 110569359
Wrong product administered 49.92 38.43 21 7484 10939 110570855
Faecaloma 49.89 38.43 23 7482 14885 110566909
Cerebrospinal fluid retention 47.83 38.43 8 7497 102 110581692
Myoclonus 45.01 38.43 28 7477 32970 110548824
Arrhythmia 43.97 38.43 37 7468 69538 110512256
Dehydration 43.20 38.43 72 7433 279439 110302355
Intentional overdose 43.18 38.43 49 7456 132452 110449342
Photopsia 42.61 38.43 16 7489 6198 110575596
Blood creatine phosphokinase increased 42.39 38.43 37 7468 73040 110508754
Parkinsonism 41.24 38.43 23 7482 22164 110559630
Tachypnoea 40.48 38.43 28 7477 39367 110542427
Disease recurrence 39.80 38.43 33 7472 60751 110521043
Drug withdrawal convulsions 39.53 38.43 12 7493 2437 110579357

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AD05 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Butyrophenone derivatives
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D012702 Serotonin Antagonists
MeSH PA D014149 Tranquilizing Agents
MeSH PA D014150 Antipsychotic Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
CHEBI has role CHEBI:48279 serotonergic antagonist
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:65190 first generation antipsychotic
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent

Related Drugs by ATC class:

N05AD Butyrophenone derivatives 8 drugs
benperidolbromperidoldroperidolhaloperidollumateperonemelperonemoperonetrifluperidol

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.93 Basic
pKa2 6.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR Ki 5.30 PDSP
Beta-2 adrenergic receptor GPCR Ki 5.30 PDSP
D(2) dopamine receptor GPCR Ki 6.94 PDSP
Alpha-2A adrenergic receptor GPCR Ki 6.07 PDSP
5-hydroxytryptamine receptor 1A GPCR ANTAGONIST Ki 5.60 IUPHAR
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.30 IUPHAR
5-hydroxytryptamine receptor 2B GPCR Ki 7.32 PDSP
5-hydroxytryptamine receptor 2C GPCR Ki 6.64 PDSP
Alpha-2B adrenergic receptor GPCR Ki 7.46 PDSP
D(3) dopamine receptor GPCR Ki 6.60 PDSP
Histamine H1 receptor GPCR ANTAGONIST Ki 5.60 IUPHAR
5-hydroxytryptamine receptor 1B GPCR ANTAGONIST Ki 6.20 IUPHAR
5-hydroxytryptamine receptor 1D GPCR ANTAGONIST Ki 6.80 IUPHAR
Alpha-2C adrenergic receptor GPCR Ki 6.54 PDSP
5-hydroxytryptamine receptor 1F GPCR Ki 5.30 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 5.30 PDSP

External reference:

IDSource
D01482 KEGG_DRUG
C0071098 UMLSCUI
CHEBI:78549 CHEBI
CHEMBL440294 ChEMBL_ID
DB09286 DRUGBANK_ID
C005569 MESH_SUPPLEMENTAL_RECORD_UI
4830 PUBCHEM_CID
92 IUPHAR_LIGAND_ID
1588 INN_ID
2448-68-2 SECONDARY_CAS_RN
5402501F0W UNII
289159 RXNORM
005709 NDDF
005710 NDDF
703362007 SNOMEDCT_US
703363002 SNOMEDCT_US
703364008 SNOMEDCT_US
5402501F0W INXIGHT DRUGS

Pharmaceutical products:

None